košarica
0.00 €Retatrutide
10 mg8% purityLot #RETATR-2026-001
Šifra odabrane dimenzije: PEP-RETA-10MG
Retatrutide (LY3437943) is an innovative triple-agonist peptide designed to activate three key metabolic hormone receptors at the same time:
GLP-1 (Glucagon-Like Peptide-1)
€303.78s PDV-om
✅ na zalihi (40)
Količinski popusti
| Količina | Cijena / kom | Ušteda |
|---|---|---|
| 1 vial | 303.78 € | — |
| 3 vials (−7%) | 283.04 € | −7% |
| 5 vials (−12%) | 267.18 € | −12% |
Ocene in mnenja
Prijavite se in ocenite izdelek po prejetem naročilu. prijava
Certifikat analize
Lab verificirano✓Pogledajte COA prije kupnje — transparentnost zajamčena
Istraživački profil
Retatrutide — znanstveni profil
Sadržaj je namijenjen obrazovnim i istraživačkim svrhama. Research Use Only.
- Retatrutide (LY3437943) is an innovative triple-agonist peptide designed to activate three key metabolic hormone receptors at the same time:
- GLP-1 (Glucagon-Like Peptide-1)
- GIP (Glucose-dependent Insulinotropic Polypeptide)
- Glucagon receptors
- By targeting all three pathways simultaneously, it introduces a first-of-its-kind mechanism that represents one of the most advanced developments in metabolic peptide research.
- Unlike dual GIP/GLP-1 agonists, retatrutide incorporates glucagon receptor activation, which substantially increases energy expenditure and promotes greater oxidation of liver fat. In a Phase 2 study published in 2023 in the New England Journal of Medicine, participants treated with retatrutide achieved an average body-weight reduction of 24.2% after 48 weeks, marking the greatest weight-loss effect reported to date for an anti-obesity therapy. The glucagon-mediated component also stimulates thermogenesis and supports liver fat clearance, with some participants experiencing complete resolution of hepatic steatosis.
